Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing BMS-986489 (BMS-986012 + nivolumab fixed-dose combination) plus carboplatin and etoposide versus atezolizumab plus carboplatin and eto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• BMS-986489
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Extensive-Stage Small Cell Lung Cancer | Phase 3 | Status: RECRUITING